Adagio Therapeutics’ Monoclonal Antibody ADG20 Has Neutralizing Activity Against Omicron

Adagio Therapeutics is a biotechnology company founded in the United States specializing in researching and commercializing antibody-based infectious diseases treatments. Today, the price is marvelously soaring to $7.11 by 21%, while the previous close was $5.83. However, in December 2021, the company experienced a strong reduction in the stock price from $34.25 to $5.62 by losing 83%. Today, the company’s stock is in the spotlight after a major announcement about the monoclonal antibody ADG20 has neutralizing activity on Omicron. In this situation, it may be a good move for investors to consider taking a closer look at the announcement.

Adagio Therapeutics

In this case, Adagio Therapeutics published three independent publications indicating that its leading monoclonal antibody (mAb) ADG20 has neutralizing activity on the Omicron of SARS-CoV-2 and outlined measures to deal with current future SARS-CoV-2 variants of concern. ADG20 is developed to treat COVID-19 and the prevention of phase 2/3 clinical trials and against Omicron. Plus, ADGI is now in discussions with the FDA to revise the study’s protocol, which includes dose escalation for its potential against the Omicron variety.